Rosacea - Pipeline Insight, 2024

This “Rosacea - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Rosacea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Rosacea Understanding

Rosacea: Overview

Rosacea is a long-term skin condition that mainly affects the face. It's more common in women and people with lighter skin, but symptoms can be worse in men. Treatment can help with symptoms. The main symptoms of rosacea are facial flushing, irritated skin, and pimples. Other symptoms include blushing easily and eye problems. There is currently no cure for rosacea, but people can treat the symptoms using creams and medications. Some foods and beverages can worsen the symptoms, such as dairy products, spicy foods, caffeine, and alcohol. Sun exposure can also make the symptoms worse. Skin creams can help reduce inflammation and skin discoloration. Doctors may recommend using them once or twice per day. Examples include topical antibiotics, tretinoin, benzoyl peroxide, and azelaic acid. Oral antibiotics can have anti-inflammatory effects. They tend to give faster results than topical ones. Examples include tetracycline, minocycline, and erythromycin. Dermatologists can use laser treatment to help reduce visible blood vessels, or telangiectasia. This treatment uses intense pulsed light to shrink them.

Rosacea - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rosacea pipeline landscape is provided which includes the disease overview and Rosacea treatment guidelines. The assessment part of the report embraces, in depth Rosacea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rosacea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Rosacea R&D. The therapies under development are focused on novel approaches to treat/improve Rosacea.

Rosacea Emerging Drugs Chapters

This segment of the Rosacea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rosacea Emerging Drugs

Epsolay: Sol-Gel TechnologiesEpsolay is a topical cream that utilizes a patented technology process to encapsulate benzoyl peroxide 5% within silica-based microcapsules. Once applied, the medication then slowly migrates from the microcapsules to deliver an effective dose of benzoyl peroxide to the skin, while also reducing skin irritation. In September of 2020, Sol-Gel was informed by the FDA that the PDUFA goal date for EPSOLAY is April 26, 2021. Subsequently, the COVID-19 pandemic restricted the FDA’s ability to conduct pre-approval inspections. Action on the NDA for EPSOLAY could not be taken since a pre-approval inspection of the production site of EPSOLAY still needs to be conducted. The Company continues to follow-up with the FDA on the scheduling of this inspection.

M 1220: Maruho Ltd.,M 1220 a topical form with an undefined mechanism is being developed and investigated in Phase III stage of development for the treatment of Papulopustular Rosacea and facial erythema of rosacea.

BMX-010: BioMimetixBMX 010, a mangano porphyrin antioxidant mimetic is being developed by BioMimetix, under a license from Duke University, for the treatment of atopic dermatitis, rosacea, and psoriasis. BMX-010 is a topical for dermatologic conditions. It is currently being investigated in Phase II clinical trial to treat rosacea.

Rosacea: Therapeutic Assessment

This segment of the report provides insights about the different Rosacea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Rosacea

There are approx. 25+ key companies which are developing the therapies for Rosacea. The companies which have their Rosacea drug candidates in the most advanced stage, i.e. Preregistration include, Sol-Gel Technologies.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Rosacea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Rosacea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rosacea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rosacea drugs.

Rosacea Report Insights

• Rosacea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Rosacea Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Rosacea drugs?
• How many Rosacea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rosacea?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rosacea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Rosacea and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2-4 business days.